Literature DB >> 19147239

Direct comparison of B-type natriuretic peptide and N-terminal pro-BNP for assessment of cardiac function in a large population of symptomatic patients.

Hun-Jun Park1, Sang Hong Baek, Sung Won Jang, Dong-Bin Kim, Dong Il Shin, Woo-Seung Shin, Pum Joon Kim, Hae-Bin Jung, Hae-Ok Jung, Ki-Bae Seung, Kyu Bo Choi.   

Abstract

BACKGROUNDS: B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NTproBNP) levels showed frequent discrepancies in individual patients.
OBJECTIVES: The aims were 1) to compare the abilities of BNP and NTproBNP for the detection of left ventricular systolic dysfunction (LVSD) or diastolic dysfunction (LVDD) in the symptomatic patients, and 2) to assess the direct correlation and its independent determinants between them.
METHODS: 1032 patients with dyspnea underwent BNP and NTproBNP measurements simultaneously. 967/1032 (93.7%) patients underwent echocardiography. Using the receiver operation characteristic curve analyses for the detection of LVSD (EF<45%) or advanced LVDD, the area under the curves (AUC) of both biomarkers was compared according to age, gender, body mass index (BMI), hemoglobin (Hb), and glomerular filtration rate (eGFR). Using multiple regression analysis, the direct correlation and its independent determinants were identified between them.
RESULTS: In the entire population, the AUCs of BNP and NTproBNP had no significant differences (LVSD: 0.909 vs. 0.893, p=0.20; advanced LVDD: 0.897 vs. 0.879, p=0.13). In patients with BMI<25, the AUCs of BNP were significantly higher than those of NTproBNP (LVSD: 0.897 vs. 0.869, p=0.03; advanced LVDD: 0.916 vs. 0.885, p=0.02). They had strong correlation (r=0.895, p<0.001) and LVEF, eGFR<60 ml/min, Hb<12 g/dl and use of diuretics were the independent determinants between them.
CONCLUSION: BNP and NTproBNP displayed strong correlation and near-identical performances for the screening of cardiac dysfunction. However, LVEF, renal function, Hb and use of diuretics should be considered for clinical interpretation. Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147239     DOI: 10.1016/j.ijcard.2008.11.107

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review.

Authors:  Ronald A Booth; Stephen A Hill; Andrew Don-Wauchope; P Lina Santaguida; Mark Oremus; Robert McKelvie; Cynthia Balion; Judy A Brown; Usman Ali; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

2.  Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NTproBNP study.

Authors:  Ahmed Saleh; Akira Matsumori; Hany Negm; Hany Fouad; Ahmed Onsy; Mohammed Shalaby; Enas Hamdy
Journal:  J Saudi Heart Assoc       Date:  2011-05-23

Review 3.  Amino-Terminal Pro-B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Renal Dysfunction: A Systematic Review and Meta-Analysis.

Authors:  Jennifer A Schaub; Steven G Coca; Dennis G Moledina; Mark Gentry; Jeffrey M Testani; Chirag R Parikh
Journal:  JACC Heart Fail       Date:  2015-12       Impact factor: 12.035

4.  Utility of NT-proBNP as a rule-out test for left ventricular dysfunction in very old people with limiting dyspnoea: the Newcastle 85+ Study.

Authors:  Joanna Collerton; Andrew Kingston; Fahad Yousaf; Karen Davies; Antoinette Kenny; Dermot Neely; Carmen Martin-Ruiz; Guy MacGowan; Louise Robinson; Thomas B L Kirkwood; Bernard Keavney
Journal:  BMC Cardiovasc Disord       Date:  2014-09-26       Impact factor: 2.298

5.  NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population.

Authors:  Maria Averina; Michael Stylidis; Jan Brox; Henrik Schirmer
Journal:  ESC Heart Fail       Date:  2022-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.